FDA approved label expansion for Teva's Ajovy, following joint CGRP-targeting drug development with Novartis.
2 reports, 2 independent
Updated Aug 7
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
FDA approved label expansion for Teva's Ajovy, following joint CGRP-targeting drug development with Novartis.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
- FDA
-
Novartis
Swiss-American multinational pharmaceutical corporation
-
Teva Pharmaceutical Industries Ltd.
Israeli pharmaceutical company
Related events
Coverage
Newest first; wire copies grouped- Pharmaceutical TechnologyTeva’s Ajovy becomes first migraine prevention drug approved for children The US Food and Drug Administration (FDA) has approved a label expansion to Teva’s Ajovy in certain children and adolescents,
- GlobeNewswireFDA Approves Expanded Indication for AJOVY® (fremanezumab-vfrm), The First Anti-CGRP Preventive Treatment for Pediatric Episodic Migraine FDA approves single-dose AJOVY® (fremanezumab-vfrm) injection